Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T Therapy for Relapsed/Refractory Systemic Sclerosis
NCT06871644Phase 1Not yet recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label trial of PA3-17 in systemic sclerosis (SSc) (3 arms), sponsored by PersonGen BioTherapeutics. Primary endpoint: Adverse Events at 1 year. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
PA3-17
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06871644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06871644.